Physician profile
David Eric Cohen
NPI 1598185142
$3,500.22
in general payments reported to CMS, 2019-2025
29 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $148 · 2021: $779 · 2022: $688 · 2023: $676 · 2024: $905 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $441.60 | 2020-2025 | |
| Boston Scientific Corporation | $422.25 | 2021-2025 | Watchman Flx, Watchman Access System |
| Amgen INC. | $310.52 | 2020-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $303.47 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $261.84 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $233.24 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $202.88 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $185.91 | 2020-2024 | Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $160.78 | 2021-2023 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.21 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $125.23 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.83 | 2020-2024 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $84.97 | 2024 | Arcalyst |
| Althera Pharmaceuticals LLC | $68.00 | 2021 | |
| Esperion Therapeutics, INC. | $64.12 | 2022-2024 | Nexletol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $54.70 | 2022-2025 | Ozempic |
| Irhythm Technologies, INC. | $44.71 | 2022 | |
| Edwards Lifesciences Corporation | $37.29 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Veryan Medical Incorporated | $31.28 | 2021 | |
| Abbott Laboratories | $31.16 | 2020-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Lexicon Pharmaceuticals, INC. | $31.15 | 2024 | |
| Astellas Pharma US INC | $30.94 | 2021-2022 | |
| Daiichi Sankyo INC. | $28.61 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $28.13 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $26.71 | 2021 | |
| Kestra Medical Technology Services, INC. | $23.20 | 2024 | Assure Wcd |
| Philips North America LLC | $19.68 | 2023 | |
| Medtronic, INC. | $13.27 | 2023 | Micra |
| Kowa Pharmaceuticals America, INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.